News Snapshot:
HDT Bio Corp. , a developer of immunotherapies for oncology and infectious diseases, announced today the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (NIH) has awarded the company a three-year, $2.9 million grant to develop an HIV-1 RNA vaccine with its proprietary Lipid InOrganic Nanoparticle (LION) delivery system. "HIV/AIDS remains a major global health challenge and is still an epidemic in some developing nations," said Steve Reed, Ph.D., President and Chief Executive Officer of HDT Bio. "While AIDS can be treated as a chronic condition, the best way to counteract a potential resurgence...
